Nvidia Gives Solid Revenue Forecast Despite China Slowdown
Good morning. Nvidia predicts sales growth despite a slowdown in China. Honor Device is going big on humanoid robots. And the next great sitcom might not be on network television, but YouTube. Listen to the day's top stories.
Nvidia climbed postmarket as investors looked past a slowdown in China to the company's upbeat revenue forecast for the current period. Sales will be about $45 billion in the fiscal second quarter—including the loss of roughly $8 billion in revenue from China because of export controls. The outlook shows that Nvidia is ramping up production of Blackwell, its latest semiconductor design. The S&P 500 and Nasdaq 100 fell before the earnings.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
25 minutes ago
- Bloomberg
Hegseth Warns About China Threat, Urges Asian Allies to Boost Defense Spending
Speaking at the Shangri-La Dialogue in Singapore, US Defense Secretary Pete Hegseth urged Washington's partners in Asia to increase defense spending and warned that "China seeks to become a hegemonic power" in the Indo-Pacific region. (Source: Other)
Fox News
40 minutes ago
- Fox News
China launches Tianwen-2 space probe to collect samples from asteroid near Mars
China has launched a space probe that will travel to an asteroid near Mars to collect samples and find potential "groundbreaking" results. The Tianwen-2 probe launched Thursday from the Xichang Satellite Launch Center in southwest China's Sichuan Province aboard the workhorse Long March 3-B rocket, according to the China National Space Administration (CNSA). The target of the Tianwen-2 will be different from its predecessor, the Tianwen-1, which launched a year ago and landed on Mars. Tianwen-2 will be aiming for the asteroid 2016 HO3, which is also known as 469219 Kamoʻoalewa, to bring back samples. The proposed 10-year plan would involve more than just this space mission as China continues to look to expand into space. Zhang Rongqiao, chief designer of the Tianwen-1, told China Central Television he plans to implement the "Tianwen-3" Mars sampling return mission in 2028, while the "Tianwen-4" will head toward Jupiter. According to The Associated Press, the asteroids, chosen for their relatively stable orbits, will hopefully offer clues about the formation of Earth, such as the origins of water. Samples from 2016HO3 are due to be returned in about two years. Even if the CNSA is going to distribute these samples to international partners like they have on previous missions, NASA wouldn't be able to receive any samples. A law passed in 2011, known as the Wolf Amendment, restricts NASA from having any cooperation with the CNSA. China also operates the three-person Tiangong, or "Heavenly Palace," space station. This gives China a step in the right direction to become a major force in the exploration of space. Its permanent station was created after being excluded from the International Space Station over U.S. national security concerns. The Associated Press contributed to this story
Yahoo
an hour ago
- Yahoo
Illuminating ctDNA-MRD: Gene Solutions' K-CONNECT APAC 2025 Sparks Regional Collaboration in Precision Oncology
DA NANG, Vietnam, May 31, 2025 /PRNewswire/ -- May 9-11, 2025, Gene Solutions, a pioneer in AI-driven precision oncology hosted K-CONNECT APAC 2025, a pivotal summit uniting over 100 distinguished oncologists and molecular biologists from nine Asia-Pacific countries. — This landmark event marked a significant milestone in advancing precision oncology, fostering collaboration, and driving innovation in the fields of circulating tumor DNA (ctDNA), Molecular Residual Disease (MRD), and Comprehensive Genomic Profiling (CGP). Under the theme "Empowering the Potential of ctDNA-MRD," 16 distinguished speakers and panelists shared clinical insights, breakthrough research, and innovative strategies for integrating ctDNA-MRD into cancer practice. "While ctDNA and MRD are invisible to the eye, K-CONNECT APAC 2025 shed transformative light on their potential through regional collaboration and clinical innovation," said Ida Deleskog Lindstrom, Global Medical Affairs Director at Gene Solutions. "Illuminating ctDNA-MRD means revealing actionable insights that spark hope, clarity, and progress through molecular insights to transform precision oncology." "K-CONNECT APAC 2025 was a transformative moment for precision oncology in the Asia-Pacific, bringing together diverse expertise to translate ctDNA-MRD advancements into real-world clinical impact'' said Professor Nick Pavlakis, Co-Chair of the summit and a leading medical oncologist from Australia. "This summit has set a new benchmark for collaborative innovation, paving the way for personalized cancer care across the region'' A First-of-Its-Kind Gathering in Asia-Pacific Gene Solutions, a regional pioneer in ctDNA-MRD testing, has supported over 6,000 cancer patients via its next generation comprehensive AI-powered K-TRACK® and K-4CARE® platforms. K-CONNECT APAC 2025 showcased its role in fostering cross-border expertise to accelerate adoption of precision diagnostics. The summit featured three key sessions shared by 16 esteemed experts K-CONNECT ACADEMIC Session: The Importance of ctDNA-MRD and CGP in Precision Oncology Unique Combination of Genomic & Transcriptomic Profiling with ctDNA-MRD Monitoring Key findings from Asia's First Real-World Study of ctDNA-MRD Monitoring in Solid Tumors. K-CONNECT CASE SHARING Session ctDNA-MRD Applications & Real-World Case Sharing in Colorectal, Lung and Breast cancers. K-CONNECT NEXT LANDMARK Session Genetic Testing Guided Personalized Immunotherapy in Refractory Solid Tumors. Triad of Impact– A Multi-omic Solution to Advance Precision Oncology Innovation. Beyond an Event — Establishing a Platform for Ongoing Impact K-CONNECT is evolving into a regional hub for knowledge exchange, clinical collaborations, and precision oncology innovation acceleration. Upcoming initiatives include: K-CONNECT Webinar Series – Ongoing expert-led case discussions Clinical Trials Collaboration – Cross-border partnerships with biopharma and research institutions Experience ctDNA-MRD Program – Hands-on implementation support for clinicians Knowledge Hub – A digital platform for APAC oncology insights Shaping the Future of Cancer Care K-CONNECT APAC 2025 solidified Gene Solutions' leadership in genetic testing and its commitment to advancing equitable access to innovative solutions to improve patient outcomes. By fostering collaboration and showcasing real-world impact, the summit laid the foundation for a more connected, data-driven, and patient-centered future in cancer care across the Asia-Pacific. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific. Explore more information at: MEDIA CONTACT: pr@ View original content to download multimedia: SOURCE Gene Solutions Genomics Pte Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
